Sponsor & Developer Portfolio
University of North Carolina, Chapel Hill
Clinical development pipeline, platform architecture, and registered trial tracking for University of North Carolina, Chapel Hill vaccine candidates.
1
Candidates
1
Target Diseases
1
Linked Studies
Development Phase Distribution
Phase 3 Clinical Trial: 1
Platform Technologies
Biological (unspecified platform): 1
Target Pathogens & Indications
Influenza
Vaccine Pipeline Candidates (1)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Phase 3 Clinical Trial
ctgov-laiv-nasal-vaccine-is-chosen-as-a-model-viral-infection-universi
LAIV nasal vaccine is chosen as a model viral infection
Target: Influenza
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2028-12-31 (registry estimate)
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.